Modulating Expression

Physicians share their techniques for obtaining better longevity and more natural-looking results with botulinum toxins.
Improving longevity and outcomes with neurotoxins

What started as a simple injection to lessen crow’s feet has blossomed into a multibillion dollar market and given rise to today’s medical aesthetics industry. With nearly 30 years of experience and a growing variety of botulinum toxins entering the market, the current focus in neuromodulation is on extending the longevity of results and delivering natural-looking outcomes.

Comparing Three Botulinum Toxins

Comparing Three Botulinum Toxins

A study in Plastic and Reconstructive Surgery (May 2016) used digital image correlation to compare dynamic strain reduction between three U.S. Food and Drug Administration (FDA)-approved formulations of botulinum toxin: onabotulinumtoxinA (Botox, Allergan), abobotulinumtoxinA (Dysport, Galderma) and incobotulinumtoxinA (Xeomin, Merz).

AbobotulinumtoxinA may offer faster onset of action and longer duration of results

A split-face study comparing the onset of action, change in degree of wrinkles, patient satisfaction, duration of effect and adverse effects of OnabotulinumtoxinA (ONA; Botox, Allergan, and AbobotulinumtoxinA (ABO; Dysport, Valeant Pharmaceuticals) has revealed subtle differences between the two popular injectables. Ramtin Kassir, MD, et al, treated 85 patients aged 18-75 with moderate to severe wrinkles in either the glabellar or crow’s feet area, or both. Patients who had conditions that would interefere with the assessment of wrinkles were excluded.